EDEM1 as A Potential Drug Target and Biomarker for Cancer (G9695)

Target Name: EDEM1

NCBI ID: G9695

EDEM1

EDEM1 as A Potential Drug Target and Biomarker for Cancer

EDEM1 (endoplasmic reticulum-associated protein 1) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the evolutionarily conserved family of transmembrane proteins known as the EDEM proteins. EDEM1 is highly conserved across various species, including humans, and is expressed in a wide range of tissues, including the brain, heart, liver, and muscle.

EDEM1 functions as a protein that plays a critical role in the regulation of cellular processes, including protein trafficking, intracellular signaling, and cell survival. It is involved in the formation of endoplasmic reticulum (ER) and in the delivery of proteins to the ER, which is the final destination for proteins that have been synthesized in the cytoplasm.

EDEM1 is also involved in the regulation of cell adhesion and in the development of cancer. Its expression is often reduced in cancer cells compared to normal cells, and it has been shown to be a potential drug target in cancer therapy.

EDEM1 as a drug target

EDEM1 has been identified as a potential drug target in cancer therapy due to its involvement in the regulation of cell adhesion and its expression is often reduced in cancer cells compared to normal cells.

One of the main mechanisms by which EDEM1 is involved in cancer is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. In cancer, abnormal cell-cell and cell-tissue adhesion can contribute to the development and progression of cancer.

EDEM1 plays a critical role in the regulation of cell adhesion by forming a complex with the protein known as ZF-21, which is a transcription factor that regulates cell adhesion. This complex helps to maintain the expression of genes that are involved in cell adhesion and in the regulation of cell-cell and cell-tissue adhesion.

Another mechanism by which EDEM1 may contribute to cancer development is its role in the regulation of cell survival. Cancer cells are able to survive and grow in an environment that is hostile to normal cells, and they do so by suppressing the expression of genes that are involved in cell growth and survival.

EDEM1 is involved in the regulation of cell survival by forming a complex with the protein known as p53, which is a transcription factor that regulates cell growth and survival. This complex helps to maintain the expression of genes that are involved in cell growth and survival, thereby contributing to the survival of cancer cells.

EDEM1 as a biomarker

EDEM1 has also been identified as a potential biomarker for cancer. Its expression is often reduced in cancer cells compared to normal cells, and it has been shown to be a reliable biomarker for the diagnosis and prognosis of several types of cancer, including breast, ovarian, and colorectal cancers.

EDEM1 can be used as a biomarker for cancer by measuring its expression in patient samples or in tissue samples from cancer patients. This can be done using techniques such as qRT-PCR, a technique that is used to measure the expression of genes in gene expression experiments, or western blotting, a technique that is used to measure the levels of specific proteins in a sample.

EDEM1 has also been shown to be involved in the regulation of cancer cell proliferation, which is a critical step in the development and progression of cancer. By measuring the levels of EDEM1 in cancer cells, researchers can determine the effectiveness of different cancer therapies and the potential for new treatments.

Conclusion

In conclusion, EDEM1 is a protein that is involved in the regulation of cellular processes, including protein trafficking, intracellular signaling, and cell survival. It is a potential drug target in cancer therapy due to its involvement in the regulation of cell adhesion and its expression is often reduced in cancer cells compared to normal cells. It

Protein Name: ER Degradation Enhancing Alpha-mannosidase Like Protein 1

Functions: Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle. It is directly involved in endoplasmic reticulum-associated degradation (ERAD) and targets misfolded glycoproteins for degradation in an N-glycan-independent manner, probably by forming a complex with SEL1L. It has low mannosidase activity, catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2

The "EDEM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDEM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets